News | March 20, 2026
LANXESS marks 40 yrs of animal disease defense 'Virkon S'
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
The conflict is also triggering a widening public health emergency
The facility is expected to become operational by FY2028-29
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Subscribe To Our Newsletter & Stay Updated
